PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
  


Boston, MA, December 9, 2008-PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has established an alliance with Safe Implementation of Treatments in Stroke (SITS) International, the world's largest network of clinical sites with specialized capabilities in the area of stroke. Through this alliance, PAREXEL's clients benefit from SITS' access to more than 800 investigator sites located in 40 countries, which are dedicated to the treatment of patients suffering from acute stroke and to the conduct of Phase II - IV stroke-related clinical studies.

"According to the World Health Organization, 15 million people suffer from stroke worldwide each year, and with the aging population, biopharmaceutical companies are turning to PAREXEL with respect to an increasing number of clinical programs focused on advancing new stroke treatments," according to Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL. "PAREXEL's alliance with SITS is representative of our dedication to providing clients with expanded capabilities in the area of stroke, including accelerated study start-up and patient recruitment for clinical development programs. We are pleased to combine our in-depth central nervous system therapeutic area expertise with the highly specialized capabilities of SITS to help clients execute stroke-related studies more efficiently on a global basis."

"In joining forces with PAREXEL, SITS looks forward to furthering the growing field of stroke research and speeding the introduction of important treatments to patients," said Nils Wahlgren, M.D., Ph.D., Chairman of SITS International. "We look forward to working with PAREXEL to implement stroke programs throughout our expanding network of sites."

The objective of SITS International is the broad implementation of evidence-based stroke care and the amplification of its effects by benchmarking against best practices to certify excellence in stroke treatment. SITS is an academic-driven international collaborative, which serves as a platform for stroke-related clinical research. Through the SITS alliance, PAREXEL offers its clients a broad range of stroke-related program options, including clinical, post marketing, and safety studies, as well as patient registries. PAREXEL leverages SITS-developed tools in feasibility study modeling and site selection for its clients' clinical studies.

For more information about PAREXEL's Clinical Research Services, visit:  

http://www.parexel.com/clinical_research.html

News

PAREXEL International Corporation, a global biopharmaceutical services provider, announced today that it has established an alliance with Safe Implementation of Treatments in Stroke (SITS) International, a worldwide network of clinical sites with specialized capabilities in the area of stroke.